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Abstract
Background: Neuropathy is believed to be a common feature of functional and inflammatory intestinal diseases.
Vasoactive intestinal peptide (VIP) is an acknowledged neuroprotective agent in peripheral, including enteric, and
central neurons. The proglucagon-like hormones glucagon-like peptide 1 and 2 (GLP1 and GLP2) belong to the
secretin/glucagon/VIP superfamily of peptides and GLP1 and GLP2 receptors are expressed in enteric neurons.
Possible neuroprotective effects of these peptides were investigated in the present study.
Methods: GLP1, GLP2 and VIP were added to cultured myenteric neurons from rat small intestine or to co-cultures
of myenteric neurons and rat peritoneal mast cells. Receptor selectivity was tested by the simultaneous presence of
a GLP1 receptor antagonist (exendin (9-39) amide) or a VIP receptor antagonist (hybrid of neurotensin 6-11 and VIP
7-28). Neuronal survival was examined using immunocytochemistry and cell counting.
Results: GLP1, GLP2 and VIP significantly and concentration-dependently enhanced neuronal survival. In addition
the peptides efficiently counteracted mast cell-induced neuronal cell death in a concentration-dependent manner.
Exendin(9-39)amide reversed GLP1-induced neuroprotection while GLP2- and VIP-induced enhanced neuronal
survival were unaffected. The VIP receptor antagonist reversed GLP1- and VIP-induced neuroprotection while the
GLP2-induced effect on neuronal survival was unaffected.
Conclusions: By activating separate receptors VIP, GLP1 and GLP2 elicit neuroprotective effects on rat myenteric
neurons cultured with or without mast cells. This implies a powerful therapeutic potential of these peptides in
enteric neuropathies with a broad spectrum of applications from autoimmunity to functional disorders.
Background
The enteric nervous system (ENS) is pivotal in the regu-
lation and coordination of gastrointestinal (GI) motility,
secretion and blood flow. GI discomfort such as nausea,
bloating, abdominal pain, constipation, diarrhea or
delayed gastric emptying are common features in func-
tional bowel diseases affecting, in particular, a large
number of diabetic patients [1]. The pathogenesis of GI
symptoms in diabetes is not fully understood but auto-
nomic neuropathy and abnormal glucose levels are
suggested to be important. In diabetic rats neurodegen-
eration [2] and apoptosis [3] occur in myenteric neu-
rons. Oxidative stress is considered the most important
factor in causing diabetes-induced enteric neuropathy
[4,5]. Collectively these studies indicate the occurrence
of diabetes-related neurodegenerative processes in the
ENS that eventually lead to neuropathy, intestinal dys-
function and GI discomfort.
Glucagon-like peptide 1 (GLP1) attracts much atten-
tion due to its effects on glucose-stimulated insulin
secretion, beta-cell proliferation and food intake. It is
currently in clinical use in patients with type II diabetes
in order to treat hyperglycemia and a number of benefi-
cial side effects e.g. weight loss due to better satiety
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beta-cells against cytokine-mediated apoptosis [7] have
been recognized. A number of observations also indicate
that GLP1 is neuroprotective in the central nervous sys-
tem [8] and clinical trials on patients with Parkinsons
disease are announced [9]. In the peripheral nervous
system GLP1 prevents experimentally induced sensory
neuropathy [10,11]. In this context it is of interest to
note that GLP1 given to patients with irritable bowel
syndrome provides an effective, on demand, relief of
acute pain attacks [12].
The incretin GLP1 is encoded within the progluca-
gon precursor and released, together with glucagon-
like peptide 2 (GLP2) in a 1:1 ratio, from L-cells in the
ileum and colon in response to food ingestion. GLP2
acts as an intestinotrophic factor mainly by stimulating
crypt cell proliferation but it also possesses anti-apop-
totic effects and enhances nutrient absorption. Protec-
tive effects of GLP2 have been explored in clinical
entities like short bowel syndrome, total parenteral
nutrition-induced intestinal atrophy and in inflamma-
tory bowel disease (IBD) [for a review see [13]]. In tri-
nitrobenzene sulfonic acid or dextran sodium sulfate
models of IBD GLP2 treatment reduces the intestinal
inflammation and counteracts inflammation-induced
loss of enteric neurons. In addition, GLP2 treatment
increases the number of vasoactive intestinal peptide
(VIP)-expressing enteric neurons and the possibility
that GLP2 effects are mediated via release of VIP is
suggested [14,15]. VIP exhibits established neuropro-
tective properties in peripheral, including enteric, and
central neurons [16-20].
Aims of the present study were to investigate possible
neuroprotective effects of GLP1, GLP2 and VIP on
myenteric neurons from adult rat small intestine. Two
different in vitro models were used. First the ability of
the three peptides to enhance neuronal survival was
tested on myenteric neurons in primary culture. Next
neuroprotective effects of the peptides were tested in an
in vitro system in which enhanced neuronal cell death
was generated by co-culturing myenteric neurons with
mast cells. Receptor selectivity was, in both these mod-
els, tested by using a GLP1 receptor antagonist (exendin
(9-39)amide) and a VIP receptor antagonist (hybrid neu-
rotensin 6-11 and VIP 7-28; hybVIP).
GLP1, GLP2 and VIP were in the present study found
to efficiently protect myenteric neurons in two different
culture systems. Separate receptors, suggested to be
neuronally expressed, were activated. These results
strongly point towards a powerful therapeutic promise
for these three peptides in the prevention of enteric
neuropathy in diseases like diabetes, but also in inflam-
matory and neurodegenerative diseases.
Methods
Animals
Female Sprague-Dawley rats (n = 38, 170-180 g), pur-
chased from Charles River, Sulzfeld, Germany, were
used. The rats were allowed to acclimatize to the cli-
mate- and light-controlled animal facility for at least 5
days prior execution. Standard rat chow and water were
supplied at all times. The experimental design was
approved by the animal ethics committee, Lund and
Malmö, Sweden. Animals were used in accordance with
the European Communities Council Directive (86/609/
EEC and 2010/63/EU) and the Swedish Animal Welfare
Act (SFS 1988:534).
Myenteric neuronal cultures
Primary cultures of myenteric neurons were prepared
from rat small intestine using a previously described
method [21]. In brief, rats were deeply anaesthetized
using chloral hydrate (300 mg/kg body weight) and the
small intestine was exposed via a midline incision. The
longitudinal muscle with attached myenteric ganglia
were stripped from approximately 20 cm of the distal
small intestine. Stripping was performed aseptically
without penetrating the gut thereby avoiding contamina-
tion by luminal fecal matter. The tissue was cut into
smaller pieces (2 × 2 mm) and washed in Ca
2+-a n d
Mg
2+-f r e eH a n k ’s balanced salt solution (HBSS, Gibco,
BRL, Life Technologies AB, St o c k h o l m ,S w e d e n ) .T i s -
sues were placed in HBSS containing collagenase II (1.5
mg/ml, Life Technologies AB) and protease (1.5 mg/ml,
Sigma-Aldrich, Stockholm, Sweden) and mechanically
separated by trituration 15 times (15×) followed by incu-
bation 25 min at 37°C in a humidified incubator holding
5% CO2. Tissue material was vortexed and trypsin (1.25
mg/mL, BioChrom, Berlin, Germany) and EDTA (0.01%,
Ethylenediaminetetraacetic acid, Sigma-Aldrich) added
and the tissue was again triturated 15× and incubated
rotating 20 min at 37°C, 5% CO2. The tissue was vor-
texed and 50% vol/vol fetal calf serum (FCS, Gibco BRL,
Life Technologies) was added. The cell suspension was
passed through a rough mesh (Ø 1 mm), centrifuged at
7.4 g for 7 min and washed in HBSS, the washing proce-
dure was repeated twice. The cell pellet was diluted to
2.5 mL in Neurobasal A (NBA) culture medium con-
taining 10% FCS, 0.5 mM L-glutamine, 50 U/mL peni-
cillin G sodium and 50 μg/mL streptomycin sulphate
(all from Gibco BRL, Life Technologies). Cell cultures
were prepared by seeding 50 μl of constantly mixed cell
suspension into 8-well chambers (cat no 734-0402, BD
Falcon, VWR, Göteborg, Sweden) prefilled with 450 μL
NBA and incubated in humidified incubator holding 5%
CO2. From each rat six 8-wells chambers (each well 69
mm
2) were prepared; cell cultures were never prepared
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days in vitro (4 DIV), 400 μL of medium was replaced
with fresh medium and, depending on experimental set
up, mast cells (see below) and/or pharmacological
agents were added. The cultures were then grown for 2
days (4 + 2 DIV) followed by fixation for 30 minutes in
a mixture of 2% formaldehyde and 0.2% picric acid (Ste-
fanini’s fixative) in 0.1 M phosphate-buffer, pH 7.2, rin-
sing twice in Tyrode’s solution containing 10% sucrose.
In order to enhance antibody penetration, the cultures
were frozen in -20°C for at least 1 h before being pro-
cessed for immunocytochemistry.
Evaluation was by neuronal cell counting. Parallel con-
trols were cultured in NBA (supplemented as described
above).
Isolation of mast cells
Adult female rats (Sprague-Dawley, 250-300 g, n = 16)
were killed by cervical dislocation. Mast cells were
obtained by peritoneal saline washings using procedures
previously described [21]. In brief, peritoneal lavage was
performed by injecting 10 mL saline containing heparin
(5 U/mL) into the peritoneal cavity followed by abdom-
inal massage for 4 min. The mast cell rich fluid
(approximately 7 mL) was removed and centrifuged at
15 g for 2 min at room temperature. Precipitated cells
were resuspended in 1 mL NBA.
Co-culturing myenteric neurons and mast cells
To 4 DIV cultures of myenteric neurons 50 μL( =1 8
988 ± 1 046 mast cells, mean ± SEM; see section “histo-
chemistry” for details) of mast cell suspension was
added. To test if GLP1, GLP2 or VIP inhibited mast
cell-induced neuronal cell death the peptides (10
-9 -1 0
-6
M) were added to the neuron-mast cell co-cultures, in
the presence or absence of receptor antagonist.
At the end of experimentation, referred to as 4 (neu-
ronal pre-culture period) + 2 (co-culture period) DIV
the cultures were fixed, rinsed (as described above) and
frozen until being processed for immunocytochemistry.
Evaluation was by neuronal cell counting after 4 + 2
DIV. Parallel controls were cultured in NBA (supple-
mented as described above) with or without addition of
mast cell and without peptides or receptor antagonists.
Pharmacological agents
To test if the presence of GLP1 (human GLP1(1-36)
amide, PolyPeptide Laboratories A/S, Hillerød, Den-
mark), GLP2 (human GLP2(1-34), PolyPeptide Labora-
tories A/S) or VIP (rat VIP, Sigma-Aldrich) affected
neuronal survival, the peptides were added separately
(10
-11-1 0
-6 M) to 4 DIV cultures or co-cultures.
Possible inhibitory effects of GLP1 receptor antagonist
exendin(9-39)amide (10
-7 M; Bachem) or VIP receptor
antagonist hybVIP (10
-9 M; hybrid neurotensin 6-11 and
VIP 7-28, Bachem, St. Helens, UK) on GLP1-, GLP2-, or
VIP- induced neuroprotection were tested by addition of
the receptor antagonist simultaneously with the peptide
studied. All substances were dissolved in sterile water.
Histochemistry
In order to estimate the number of mast cells seeded in
each well, 50 μL of the mast cell suspension was placed on
a glass slide. Two such slides were performed from each
rat. The slides were dried (30 min in 37°C), fixed and
rinsed as described above. To detect mast cells the slides
were stained 10 min with 0.1% toluidine blue (CI 52 040).
Mast cells become deep purple due to metachromasia.
The number of mast cells per slide was estimated by com-
puterized morphometry [21]. The total number of mast
cells seeded (in 50 μL mast cell suspension) was found to
be 18 988 ± 1 046 mast cells (mean ± SEM; n = 4).
Immunocytochemistry
As general neuronal markers antibodies against HuC/
HuD (a mouse monoclonal anti-human neuronal pro-
tein; code no A-21271; Molecular Probes, Eugene, OR,
USA; dilution 1:400; [22]) or human protein gene pro-
duct 9.5 (raised in rabbit, code no PGP9.5; Ultraclone,
Isle of Wight, UK; dilution 1:1600; [21]) were used. In
terms of number of nerve cell bodies visualized in vitro
the HuC/HuD and the PGP 9.5 antibodies gave identical
results, as previously described [23]. Mast cells were
detected by antibodies raised in rabbits against hista-
mine coupled to human serum albumin using carbodii-
mide (code no 8432, Euro-Diagnostica AB, Malmö,
Sweden; dilution 1:300; [24]).
Immunolabeling was done by incubation of the slides
with primary antibodies in a moist chamber over night at
4°C. For visualization, the slides were exposed to fluores-
cein isothiocyanate (FITC)- or Texas Red- conjugated goat
anti-rabbit IgG antiserum (Jackson Immunoresearch
Laboratories, West Grove, PA, USA; dilution 1:100) or
FITC conjugated goat anti-mouse IgG antiserum (Jackson
Immunoresearch Laboratories; dilution 1:100) for 1 h,
mounted in phosphate buffer:glycerol 1:1 and analyzed
using a fluorescence microscope with appropriate filter
settings. Since synthetic antigens for testing the specifici-
ties of the HuC/HuD and PGP9.5 are not commercially
available, omission of primary antibodies was used as con-
trol. In order to assess the specificity of the histamine anti-
serum 10 μM histamine was incubated with the antibodies
(dilution 1:300) over night before being exposed to the
slides. Controls did not exhibit any immunostaining.
Cell counting and statistical analysis
Neuronal survival was calculated by counting the num-
bers of surviving neurons in the entire culture chamber
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agents and expressed in percentage of the control run in
parallel.
Statistical differences were determined using one-way
analysis of variance test (ANOVA) followed by Dun-
nett’s multiple comparison test (all comparisons against
control column). Statistical analysis was performed
using GraphPad Prism 5 (GraphPad Software Inc., San
Diego, CA, USA)
Results
Myenteric neurons in culture and in co-culture with mast
cells
Neurons cultured for 4 + 2 days stained well with both
HuC/HuD and PGP9.5 and were uniformly dispersed
throughout the culture wells. Neurons with rich net-
works of arborizing fibers were displayed after staining
with PGP 9.5 antibodies (Figure 1A), while HuC/HuD
antibodies revealed nerve cell bodies only. The number
of neurons was 4.9 ± 0.4 neurons/mm
2 (n = 24), as
established on parallel controls.
Addition of mast cells to pre-cultured (4 DIV)m y e n -
teric neurons resulted in a disintegrated nerve fibre net-
work and a markedly enhanced loss of nerve cell bodies
(Figure 1B). After 2 days in co-culture (4 + 2 DIV)t h e
numbers of myenteric neurons were reduced to 2.4 ±
0.2 neurons/mm
2 (n = 24), p <0 . 0 1a sc o m p a r e dt o
neurons grown in parallel without the addition of mast
cells.
Within the co-cultures mast cells dispersed uniformly,
survived well and adhered to the bottom of the culture
chambers. When stained with histamine antibodies or
toluidine blue the mast cells were found to contain
numerous granules within the cytoplasm (Figure 1C).
Cultured mast cells often showed signs of degranulation
and some exhibited piece meal degranulation (Figure
1D). Mast cells and neurons were occasionally seen in
close proximity (Figures 1E and 1F).
Survival of neurons after GLP1, GLP2 or VIP treatment
Myenteric neurons pre-cultured for 4 days, followed by
exposure to GLP1, GLP2 or VIP in different concentra-
tions (10
-11-10
-6 M) for 2 days (4 + 2 DIV), showed a
markedly increased neuronal survival, compared to
untreated controls run in parallel. The increase was con-
centration-dependent for all three peptides. EC50 (M)
values were 3 × 10
-11 for GLP1, 3.5 x10
-10 for GLP2 and
4×1 0
-11 for VIP. Emax (%; maximal neuronal survival
as a percentage of control) values were 178.5 ± 14.0 for
GLP1, 150.8 ± 6.0 for GLP2 and 150.4 ± 8.4 for VIP.
Peptide receptor selectivity was tested in experiments
using receptor antagonists for either GLP1 (10
-7 M,
exendin(9-39)amide) or VIP (10
-9 M, hybVIP) receptors
added simultaneously with the different peptides. In
these experiments both the GLP1- and the VIP- recep-
tor antagonists inhibited GLP1-induced increases in
neuronal survival. GLP2-induced survival was unaffected
by the addition of any of the two antagonists. VIP-
induced survival was unaffected by the addition of exen-
din(9-39)amide but markedly attenuated by the addition
of hybVIP. The results are summarized in Figure 2.
Survival of neurons co-cultured with mast cells in the
presence of GLP1, GLP2 or VIP
Presence of GLP1, GLP2 or VIP (10
-9-10
-6 M) within
the co-cultures of myenteric neurons and mast cells sig-
nificantly and concentration-dependently enhanced neu-
ronal survival. At the highest concentration (10
-6 M) all
three peptides were able to completely reverse mast
cell-induced neuronal cell death, as compared to neu-
rons cultured in parallel in the absence of mast cells.
Simultaneous presence of exendin(9-39)amide (10
-7 M)
counteracted the effects of GLP1 while GLP2- or VIP-
induced enhanced neuronal survival was unaffected.
Addition of hybVIP (10
-9 M) to the co-cultures ham-
pered both GLP1- and VIP-induced neuroprotection.
Results are summarized in Figure 3.
Discussion
GLP1, GLP2 and VIP promote neuronal survival
Our studies show that GLP1, GLP2 and VIP all were
able to enhance survival of myenteric neurons in cul-
ture. Further all three peptides counteracted mast cell-
induced neuronal cell death. Neuroprotection induced
by GLP1 was reversed by either the addition of the
GLP1 receptor antagonist, or the VIP receptor antago-
nist. GLP2-induced neuroprotection was unaffected by
both the receptor antagonists, and VIP-induced neuro-
protection was attenuated only by the VIP receptor
antagonist. Taken together these results indicate that
GLP1, GLP2 and VIP receptors are operating to pro-
mote neuronal survival in the ENS. GLP1 receptors are
suggested to be localized on VIP-expressing myenteric
neurons and to release VIP on activation, or act on a
parallel pathway which converges with VIP-signaling to
a common final mechanism. This is supported by the
fact that GLP1-induced neuroprotective responses were
blocked by the addition of the GLP1 receptor blocker
exendin(9-39)amide, as well as by VIP receptor antago-
nist. VIP and GLP2 receptors are suggested to evoke
direct protective effects on myenteric neurons upon
activation.
The peptide concentrations studied verified the EC50
values to be clearly within the in vivo plasma concentra-
tion range in both man and rat as shown for GLP1
[25,26], GLP2 [25,27] and VIP [28,29].
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The finding that VIP promotes neuronal survival of
myenteric neurons in vitro is well in line with several
previous observations [16,17,19,20]. Also the finding
that the presence of VIP rescues myenteric neurons
from mast cell-induced death is supported by previous
findings [21]. VIP-mediated neuroprotective effects are
in addition corroborated by several other studies per-
formed in neurons belonging to the central nervous sys-
tem [reviewed in [18]]. The receptor(s) by which VIP
mediates neuroprotection is, however, enigmatic. Clon-
ing of receptors for the VIP superfamily of peptides has
revealed three distinct receptors activated by VIP;
VPAC1,V P A C 2 and PAC1 receptors [30]. All three are
Figure 1 Immunocytochemical staining of myenteric neurons cultured in absence (A) or presence (B-F) of peritoneal mast cells.A .
Neurons grown for 6 days and stained with PGP9.5. The cultured neurons survive well; they group into ganglion-like structures and grow a
prominent arborizing network of nerve terminals. B. Neurons co-cultured with mast cells (arrows) stained with antibodies against PGP9.5 and
histamine, respectively. In the neuronal cultures to which mast cells have been added the number of neurons markedly decreases and the
terminal network is disintegrated. C and D. show mast cells grown in co-culture and stained with histamine antibodies. The mast cells are well
settled within the cultures and they contain a high number of cytoplasmic granules. C. illustrates a cultured mast cell with numerous granules in
the central, perinuclear, portion of the cell. D. shows a mast cell exhibiting piece meal degranulation. E and F. illustrate the morphological
relationship of cultured neurons and mast cells. E. shows mast cells (arrowheads) in close contact with nerve terminals from nearby myenteric
neurons (arrows). F. a mast cell and a nerve cell body in close proximity. In order to perceive the morphological arrangement of mast cells and
neurons both PGP9.5- and histamine- immunoreactive cells are visualised by FITC conjugated antibodies. Neurons and mast cells are
distinguished by their morphological characteristics. Bar in A 100 μm represents also B, bar in C 40 μm represents also D, bar in E 50 μm
represents also F.
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Page 5 of 10Figure 2 Survival of myenteric neurons pre-cultured for 4 days followed by 2 days of culture in various concentrations (10
-11-1 0
-6 M)
of GLP1, GLP2 or VIP in the absence or presence of GLP1 receptor antagonist (exendin(9-39)amide, 10
-7 M) or VIP receptor
antagonist (hybVIP, 10
-9 M). Presence of GLP1, GLP2 and VIP significantly and concentration-dependently increase neuronal survival.
Simultaneous addition of exendin(9-39)amide attenuates GLP1-induced neuroprotection while that of GLP2 and VIP are unaffected. Simultaneous
addition of hybVIP attenuates GLP1- and VIP-induced neuroprotection while that of GLP2 is unaffected. Means ± SEM, n = 6-21; * p < 0.1; ** p <
0.05; *** p < 0.01 as compared to controls run in parallel without addition of peptides or antagonists.
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Page 6 of 10Figure 3 Survival of neurons pre-cultured for 4 days followed by 2 days of culture in the absence (▲) or presence of mast cells (■,
indicated by horizontal bar in each graph). During the co-culture period the effects of GLP1, GLP2 and VIP (10
-9-1 0
-6 M), in the absence or
presence of GLP1 receptor antagonist (exendin(9-39)amide, 10
-7 M) or VIP receptor antagonist (hybVIP, 10
-7 M), on neuronal survival were
determined by neuronal cell counting. With increasing concentrations all three peptides were able to reverse mast cell-induced neuronal cell
death (denoted ns; no significant difference). Simultaneous presence of exendin(9-39)amide (10
-7 M) counteracted the effects of GLP1 while
GLP2- or VIP-induced neuroprotection was unaffected. Addition of hybVIP (10
-9 M) to the co-cultures hampered GLP1- and VIP-, but not GLP2-,
induced neuroprotection. Means ± SEM, n = 5-12; ns, no significant difference; * p < 0.1; ** p < 0.05; *** p < 0.01 as compared to controls run in
parallel (▲) without addition of mast cells, peptides or antagonists.
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cyclase-activating peptide (PACAP). Therefore the
report that, in contrast to VIP, presence of PACAP does
not elicit any neuroprotective effect on cultured rat
myenteric neurons [19] led to the suggestion of “VIP
specific” receptors. In the present study we have used a
commercially available competitive antagonist of VIP-
binding. The antagonist, a chimeric peptide consisting
of neurotensin (6-11) and VIP (7-28), was found to
antagonize the “VIP specific” receptor mediated neuro-
protective effect on cultured rat myenteric neurons.
Thus, this antagonist is suggested to have a broad spec-
trum resembling (N-stearyl, norleucine17)VIPhybrid
w h i c hr e c o g n i z e sb o t hV P A C 1 and VPAC2 receptors as
well as PAC1 receptors [31].
GLP1 receptors
GLP1 receptor stimulation is widely used clinically to
improve glucose homeostasis in patients with type 2 dia-
betes [6,32] but has also been recognized to mediate
neuroprotection and neurotrophic effects. GLP1 was
first described to protect central neurons against excito-
toxicity [33,34] but later also to have neuroprotective
properties in neurodegenerative diseases like Alzheimer’s
and Parkinson’s diseases [9]. Protective effects of GLP1
on peripheral neurons have so far only been described
in sensory neurons [10,11].
A single GLP1 receptor, similar in rodents and man,
has been cloned [35]. It is a 7-transmembrane G-protein
coupled receptor with structural similarities to the GLP2
receptor. GLP1 receptors are widely expressed through-
out the body in e.g. digestive tract, kidney and in per-
ipheral as well as central neurons [35]. Myenteric
neurons in both small and large intestine of mice
express GLP1 receptors [36]. In the present study we
suggest, based on the ability of both hybVIP and exen-
din(9-39)amide to antagonize the GLP1-induced neuro-
protective effects, that GLP1 binds to GLP1 receptors
localized on VIP-expressing myenteric neurons, thereby
causing release of VIP. The thus released VIP is respon-
sible for GLP1-induced neuroprotection of cultured
myenteric neurons.
T h ef i n d i n gt h a tG L P 1 ,b yw a yo fV I Pr e l e a s e ,e x e -
cutes neuroprotection on myenteric neurons highlights
the possibility of additional beneficial effects activated
by the use of GLP1 receptor stimulation to achieve bet-
ter metabolic control in type 2 diabetes clinically. Such
treatment would provide neuroprotection of the ENS
which may be speculated to attenuate diabetic neuropa-
thy in the GI tract. In this context it is of interest also
to note the fact that enteric myenteric neurons issue
intestinofugal projections to pancreatic ganglia [37] and
that VIP stimulates insulin release from pancreatic islets
[38]. GLP1 stimulation of VIP-expressing enteric
neurons may thus be yet another mechanism by which
GLP1 analogue-based therapies execute beneficial effects
on insulin release and glucose homeostasis.
GLP2 receptors
Within the GI tract GLP2 has significant intestino-
trophic effects involving diverse cellular organisations
despite the finding that GLP2 receptors are mainly loca-
lized on enteric neurons, endocrine cells and subepithe-
lial myofibroblasts [39]. The restricted GLP2 receptor
distribution has led to the proposal that the multitude
of GLP2-induced effects is mediated by indirect media-
tors and diverse signaling pathways [40]. One such med-
iator is VIP. In mouse, GLP2-induced gastric relaxation
is executed by prejunctional neuronal VIP release [41].
GLP2 has further been found to attenuate inflamma-
tion-induced intestinal damage and levels of proinflam-
matory cytokines in animal models of intestinal
inflammation via release of VIP [14,15]. GLP2 further
prevents loss of submucous neurons in inflamed bowel
and increases the proportion of VIP-expressing neurons
within submucous ganglia in both inflamed and non-
inflamed bowel [15]. The neuroprotective effect of GLP2
demonstrated in vivo on submucous neurons is well in
agreement with our present in vitro findings indicating
significantly improved neuronal survival and a rescue
from mast cell-induced neuronal cell death of cultured
myenteric neurons when exposed to GLP2. The data
presented here suggests that GLP2-induced neuropro-
tection of myenteric neurons is mediated by direct sti-
mulation of neuronal GLP2 receptors and not executed
by VIP release or by activation of GLP1 receptors. This
since the GLP2-induced increase in neuronal survival
was unaffected by the presence of hybVIP and exendin
(9-39)amide. However, we cannot definitely exclude
indirect mediators derived from e.g. enteric glia. Such
cells are unavoidably present within the primary cultures
of myenteric neurons as well as within the co-cultures
consisting of mast cells and neurons. A similar dilemma
concerning direct vs indirect GLP2 effects is faced by
the in vivo studies on experimental colitis [15]. In these
studies the GLP2 neuroprotective effect on submucous
neurons was suggested to be either direct or due to the
general anti-inflammatory effects caused by systemic
GLP2 treatment. In addition to enteric neurons GLP2-
mediated neuroprotective effects have also been demon-
strated in central, i.e. hippocampal, neurons [42,43] sig-
nifying that GLP2 receptor stimulation may promote
survival in different types of neurons.
GLP1, GLP2 and VIP rescue neurons from mast cell-
induced cell death
Although mast cells have been ascribed a role in the
metabolic syndrome and type 2 diabetes
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nal survival in co-cultures of myenteric neurons and
mast cells was to test VIP, GLP1 and GLP2 effects in an
in vitro setting in which neuronal cell death was actively
enhanced. Mast cells have been shown to induce death
of myenteric neurons in vitro by way of degranulation
and also by release of mediators not stored within gran-
ula. Prostaglandin D2 and interleukin-6, known mast
cells mediators, induce death of myenteric neurons in
vitro as do proteinase-activated receptor2 activation [21].
The mechanisms by which GLP1, GLP2 and VIP rescue
myenteric neurons from mast cell-induced cell death
needs further examination but is probably executed by
direct activation of neuronal receptors, as in neuronal
cultures without the addition of mast cells. The effects
of the peptides are mediated via activation of separate
receptors in both experimental models used in the pre-
sent study. It may be speculated that GLP1, GLP2 and
VIP, in the co-cultures, have direct e.g. stabilizing effects
on mast cells but present data does not substantiate
such speculations. Whether mast cells express GLP1 or
GLP2 receptors is at present unknown. Human mast
cells in culture express VIP receptors of VPAC2 type
which, upon activation, cause mast cell degranulation
[45]. Given that this applies also to cultured rat mast
cells then VIP exposure would be suspected to cause an
even more severe neuronal cell loss within the neuron-
mast cell co-cultures. In this context it is noteworthy
that brain mast cells, upon VIP activation, are suggested
to participate in central neuronal protection by adopting
a nondegranulating phenotype [46]. Thus the detailed
mechanisms behind the VIP-induced neuroprotection,
as well as that induced by the GLPs, are still unresolved.
Conclusions
The neuroprotective effects of the GLPs and VIP on
myenteric neurons are powerful and worthy of further
exploration in view of the large number of patients
facing enteric neuropathy. Neuroprotection of the ENS
is in the present work recognized as yet another positive
effect resulting from incretin-based therapies.
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